Characterization of mesenchymal stem cells in mucolipidosis type II (I-cell disease)
Mucolipidosis type II (ML-II, I-cell disease) is a fatal inherited lysosomal storage disease caused by a deficiency of the enzyme N-acetylglucosamine-1-phosphotransferase. A characteristic skeletal phenotype is one of the many clinical manifestations of ML-II. Since the mechanisms underlying these skeletal defects in ML-II are not completely understood, we hypothesized that a defect in osteogenic differentiation of ML-II bone marrow mesenchymal stem cells (BM-MSCs) might be responsible for this skeletal phenotype. Here, we assessed and characterized the cellular phenotype of BM-MSCs from a ML-II patient before (BBMT) and after BM transplantation (ABMT), and we compared the results with BM-MSCs from a carrier and a healthy donor. Morphologically, we did not observe differences in ML-II BBMT and ABMT or carrier MSCs in terms of size or granularity. Osteogenic differentiation was not markedly affected by disease or carrier status. Adipogenic differentiation was increased in BBMT ML-II MSCs, but chondrogenic differentiation was decreased in both BBMT and ABMT ML-II MSCs. Immunophenotypically no significant differences were observed between the samples. Interestingly, the proliferative capacity of BBMT and ABMT ML-II MSCs was increased in comparison to MSCs from age-matched healthy donors. These data suggest that MSCs are not likely to cause the skeletal phenotype observed in ML-II, but they may contribute to the pathogenesis of ML-II as a result of lysosomal storage-induced pathology.
___
- Amalfitano A, Bengur AR, Morse RP, Majure JM, Case LE et al. (2001).
Recombinant human acid alpha-glucosidase enzyme therapy for
infantile glycogen storage disease type II: results of a phase I/II
clinical trial. Genetics in Medicine 3: 132-138.
- Beck M (2007). New therapeutic options for lysosomal storage
disorders: enzyme replacement, small molecules and gene
therapy. Human Genetics 121: 1-22.
- Bhatt VR, Vose JM (2014). Hematopoietic stem cell transplantation
for non-Hodgkin lymphoma. Hematology/Oncology Clinics of
North America 28: 1073-1095.
- Flanagan-Steet H, C Sias, R. Steet (2009). Altered chondrocyte
differentiation and extracellular matrix homeostasis in a
zebrafish model for mucolipidosis II. American Journal of
Pathology 175: 2063-2075.
- Hickman S, Neufeld EF (1972). A hypothesis for I-cell disease:
defective hydrolases that do not enter lysosomes. Biochemical
and Biophysical Research Communications 49: 992-999.
- Infante A, Rodriguez CI (2018). Osteogenesis and aging: lessons from
mesenchymal stem cells. Stem Cell Research and Therapy 9: 244.
- Jeong SY, Seol DW (2008). The role of mitochondria in apoptosis.
BMB Reports 41: 11-22.
- Karsenty G, Kronenberg HM , Settembre C (2009). Genetic control
of bone formation. Annual Review of Cell and Developmental
Biology 25: 629-648.
- Koehne T, Markmann S, Schweizer M, Muschol N, Friedrich RE
et al. (2016). Mannose 6-phosphate-dependent targeting of
lysosomal enzymes is required for normal craniofacial and
dental development. Biochimica et Biophysica Acta 1862:
1570-1580.
- Kollmann K, Pestka JM, Kuhn SC, Schone E, Schweizer M
et al. (2013). Decreased bone formation and increased
osteoclastogenesis cause bone loss in mucolipidosis II. EMBO
Molecular Medicine 5: 1871-1886.
- Köse S, Aerts-Kaya F, Köprü CZ, Nemutlu E, Kuşkonmaz B et al.
(2018). Human bone marrow mesenchymal stem cells secrete
endocannabinoids that stimulate in vitro hematopoietic stem
cell migration effectively comparable to beta-adrenergic
stimulation. Experimental Hematology 57: 30-41.e1.
- Kudo M, Brem MS, Canfield WM (2006). Mucolipidosis II (I-cell
disease) and mucolipidosis IIIA (classical pseudo-hurler
polydystrophy) are caused by mutations in the GlcNAcphosphotransferase alpha / beta -subunits precursor gene.
American Journal of Human Genetics 78: 451-463.
- Lecourt S, Vanneaux V, Cras A, Freida D, Heraoui D et al. (2012). Bone
marrow microenvironment in an in vitro model of Gaucher
disease: consequences of glucocerebrosidase deficiency. Stem
Cells and Development 21: 239-248.
- Lee W, O’Donnell D (2003). Severe gingival hyperplasia in a child
with I-cell disease. International Journal of Paediatric Dentistry
13: 41-45.
- Leroy JG, Spranger JW, Feingold M, Opitz JM, Crocker AC (1971).
I-cell disease: a clinical picture. Journal of Pediatrics 79: 360-
365.
- Lucarelli G, Isgro A, Sodani P, Gaziev J (2012). Hematopoietic stem
cell transplantation in thalassemia and sickle cell anemia. Cold
Spring Harbor Perspectives in Medicine 2: a011825.
- Lund TC, Cathey SS, Miller WP, Eapen M, Andreansky M et al.
(2014). Outcomes after hematopoietic stem cell transplantation
for children with I-cell disease. Biology of Blood and Marrow
Transplantion 20: 1847-1851.
- Maas M, Hollak CE, Akkerman EM, Aerts JM, Stoker J et al. (2002).
Quantification of skeletal involvement in adults with type I
Gaucher’s disease: fat fraction measured by Dixon quantitative
chemical shift imaging as a valid parameter. American Journal
of Roentgenology 179: 961-965.
- Maatta A, Jarvelainen HT, Nelimarkka LO, Penttinen RP (1994).
Fibroblast expression of collagens and proteoglycans is altered
in aspartylglucosaminuria, a lysosomal storage disease.
Biochimica et Biophysica Acta 1225: 264-270.
- Mazrier H, Van Hoeven M, Wang P, Knox VW, Aguirre GD et al.
(2003). Inheritance, biochemical abnormalities, and clinical
features of feline mucolipidosis II: the first animal model of
human I-cell disease. Journal of Heredity 94: 363-373.
- McKusick VA (2007). Mendelian Inheritance in Man and its online
version, OMIM. American Journal of Human Genetics 80: 588-
604.
- Moerman EJ, Teng K, Lipschitz DA, Lecka-Czernik B (2004). Aging
activates adipogenic and suppresses osteogenic programs in
mesenchymal marrow stroma/stem cells: the role of PPAR-γ2
transcription factor and TGF-β/BMP signaling pathways.
Aging Cell 3: 379-389.
- Nishimura F, Naruishi H, Naruishi K, Yamada T, Sasaki J et al. (2002).
Cathepsin-L, a key molecule in the pathogenesis of druginduced and I-cell disease-mediated gingival overgrowth: a
study with cathepsin-L-deficient mice. American Journal of
Pathology 161: 2047-2052.
- Otomo T, Higaki K, Nanba E, Ozono K, Sakai N (2009). Inhibition
of autophagosome formation restores mitochondrial function
in mucolipidosis II and III skin fibroblasts. Molecular Genetics
and Metabolism 98: 393-399.
- Pastores GM, Meere PA (2005). Musculoskeletal complications
associated with lysosomal storage disorders: Gaucher disease
and Hurler-Scheie syndrome (mucopolysaccharidosis type I).
Current Opinion in Rheumatology 17: 70-78.
- Pazzaglia UE, Beluffi G, Castello A, Coci A, Zatti G (1992). Bone
changes of mucolipidosis II at different ages. Postmortem study
of three cases. Clinical Orthopaedics Related Research 283-290.
- Petrey AC, Flanagan-Steet H, Johnson S, Fan X, De la Rosa M et
al. (2012). Excessive activity of cathepsin K is associated with
cartilage defects in a zebrafish model of mucolipidosis II.
Disease Model and Mechanisms 5: 177-190.
- Poulopoulos A, Kittas D, Sarigelou A (2011). Current concepts on
gingival fibromatosis-related syndromes. Journal of Investigative
and Clinical Dentistry 2: 156-161.
- Schiffmann R (2010). Therapeutic approaches for neuronopathic
lysosomal storage disorders. Journal of Inherited Metabolic
Disease 33: 373-379.
- Schiffmann R, Murray GJ, Treco D, Daniel P, Sellos-Moura M et
al. (2000). Infusion of alpha-galactosidase A reduces tissue
globotriaosylceramide storage in patients with Fabry disease.
Proceedings of the National Academy of Sciences of the United
States of America 97: 365-370.
- Singh A, Prasad R, Gupta AK, Sharma A, Alves S et al. (2017). I
Cell disease (mucolipidosis II alpha/beta): from screening to
molecular diagnosis. Indian Journal of Pediatrics 84: 144-146.
Tardy C, Andrieu-Abadie N, Salvayre R, Levade T (2004a). Lysosomal
storage diseases: is impaired apoptosis a pathogenic mechanism?
Neurochemical Research 29: 871-880.
- Tardy C, Autefage H, Garcia V, Levade T, Andrieu-Abadie N (2004b).
Mannose 6-phosphorylated proteins are required for tumor
necrosis factor-induced apoptosis: defective response in I-cell
disease fibroblasts. Journal of Biological Chemistry 279: 52914-
52923.
- Terman A, Neuzil J, Kagedal K, Ollinger K, Brunk UT (2002).
Decreased apoptotic response of inclusion-cell disease
fibroblasts: a consequence of lysosomal enzyme missorting?
Experimental Cell Research 274: 9-15.
- Tomatsu S, Montano AM, Oguma T, Dung VC, Oikawa H et al.
(2010). Validation of disaccharide compositions derived from
dermatan sulfate and heparan sulfate in mucopolysaccharidoses
and mucolipidoses II and III by tandem mass spectrometry.
Molecular Genetics and Metabolism 99: 124-131.
- Tondeur M, Libert J, Vamos E, Van Hoof F, Thomas GH et al.
(1982). Infantile form of sialic acid storage disorder: clinical,
ultrastructural, and biochemical studies in two siblings.
European Journal of Pediatrics 139: 142-147.
- Tondeur M, Vamos-Hurwitz E, Mockel-Pohl S, Dereume JP, Cremer
N et al. (1971). Clinical, biochemical, and ultrastructural studies
in a case of chondrodystrophy presenting the I-cell phenotype in
tissue culture. Journal of Pediatrics 79: 366-378.
- Uckan D, Kilic E, Sharafi P, Kazik M, Kaya F et al. (2009). Adipocyte
differentiation defect in mesenchymal stromal cells of patients
with malignant infantile osteopetrosis. Cytotherapy 11: 392-402.
- Wang P, Mazrier H, Caverly Rae J, Raj K, Giger U (2018). A GNPTAB
nonsense variant is associated with feline mucolipidosis II (I-cell
disease). BMC Veterinary Research 14: 416.
- Wayne AS, Baird K, Egeler RM (2010). Hematopoietic stem cell
transplantation for leukemia. Pediatric Clinics of North America
57: 1-25.
- Wynn R (2011). Stem cell transplantation in inherited metabolic
disorders. Hematology American Society of Hematology
Education Program 2011: 285-291.